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A B S T R A C T
The aim of this study was to investigate the eﬀects of adding group acceptance and commitment therapy (ACT)
to adults diagnosed with obsessive compulsive disorder (OCD) who were already on an optimal dose of selective
serotonin reuptake inhibitors (SSRIs).
Forty-six Iranian women, on SSRIs, were randomized to group ACT + SSRI or continued SSRI conditions.
SSRI dosages stayed stable during the study. Assessments included the Structured Clinical Interview (SCID-I),
Yale-Brown Obsessive-Compulsive Scale Self report (Y-BOCS-SR), Beck Depression Inventory-II (BDI-II),
Ruminative Response Scale (RRS), and Acceptance and Action Questionnaire (AAQ-II). The results showed
signiﬁcant reductions on the Y-BOCS-SR and BDI-II in both conditions at posttreatment with signiﬁcantly greater
reductions in the ACT + SSRI condition at follow-up. The RRS and AAQ-II saw signiﬁcant improvements in the
ACT + SSRI condition at posttreatment and follow-up compared to the SSRI condition. Results provide cross-
cultural support for group ACT as a treatment for OCD and as a successful adjunct to SSRI treatment.
1. . Introduction
Obsessive-Compulsive Disorder (OCD) is a debilitating condition for
many individuals. It involves recurrent obsessions that are quelled
through recurrent compulsive actions. This pattern of behavior often
negatively eﬀects quality of life (Cicek, Cicek, Kayhan, Uguz, & Kaya,
2013). Selective Serotonin Reuptake Inhibitors (SSRIs) are eﬀective
pharmacological treatments for OCD (Soomro, Altman,
Rajagopal, & Oakley Browne, 2008). Nevertheless, meta-analyses in-
dicate that behavioral therapies and behavioral therapies plus SSRIs are
more eﬀective than SSRIs alone (Romanelli, Wu, Gamba,
Mojtabai, & Segal, 2014). Behavioral therapies that include exposure
and response prevention (ERP) with or without an emphasis on cog-
nitive procedures are the most supported treatments for OCD (Olatunji,
Davis, Powers, & Smits, 2013). In addition, Acceptance and Commit-
ment Therapy (ACT; Hayes, Strosahl, &Wilson, 2012), a modern ver-
sion of CBT, is also showing success in the treatment of OCD (Bluett,
Homan, Morrison, Levin, & Twohig, 2014). There is also some evidence
suggesting that ACT for anxiety or OCD works through predicted
processes of change (Arch, Wolitzky-Taylor, Eifert, & Craske, 2012;
Twohig, Vilardaga, Levin, & Hayes, 2015; Wolitzky-Taylor, Arch,
Rosenﬁeld, & Craske, 2012). Thus, ACT for OCD continues to be worthy
of further study.
A relationship between OCD and psychological ﬂexibility, the key
process of change in ACT, has been demonstrated with a meta-analysis
ﬁnding a correlation of r = .36 between psychological ﬂexibility and
OCD severity. Additionally, data from a handful of studies has shown
associations between improved psychological ﬂexibility and OCD se-
verity (see Bluett et al., 2014; Haaland et al., 2017). In the largest
western trial of ACT for OCD to date, eight sessions of ACT, without in-
session exposure exercises, was compared to progressive muscle re-
laxation (Twohig et al., 2010). Results showed that ACT was more ef-
fective than the control condition, with 46–56% (depending on ana-
lysis) of participants responding at posttreatment and 46–66% at follow
up, compared to 13–18% at posttreatment and 16–18% at follow up for
the control condition. Much of the research on ACT for OCD has oc-
curred within one research group, limiting the generalizability of the
results. However, recently, multiple researchers out of Iran have
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systematically studied ACT for OCD in their country.
The work in Iran—by multiple research groups—started with the
treatment of ﬁve adults with OCD using 10 individual sessions of ACT
(Izadi, Asgari, Neshatdust, & Abedi, 2012). Individual tracking of data
showed notable decreases in compulsions for all ﬁve participants and
average scores on the Yale Brown Obsessive Compulsive Inventory (Y-
BOCS, (Goodman et al., 1989) were 30 at pre, 15 at post, and 15 at
follow-up. Another small study by the same lead author included three
treatment-resistant adults with OCD who were treated using 14 in-
dividual sessions of ACT (Izadi & Abedi, 2013). Individual tracking
showed pretreatment, posttreatment, and follow up scores of 32, 20,
and 19.7 on the Y-BOCS. In a large randomized trial, 90 adults with
OCD were randomized to one of three treatments: group ACT, clomi-
pramine (a tricyclic antidepressant), or group ACT + clomipramine
(Baghooli, Dolatshahi, Mohammadkhani, Moshtagh, & Naziri, 2014).
Results were as follows for pretreatment, posttreatment, and follow-up
on the Y-BOCS: ACT 24, 14, and 11; clomipramine 25, 17, 14; ACT +
clomipramine 25, 15, 13. Between condition eﬀect sizes for ACT vs
clomipramine were as follows, posttreatment (d = .87) and follow-up
(d = .42), and the combined condition at posttreatment (d = .28) and
follow-up (d = .35). This study was replicated testing a selective ser-
otonin reuptake inhibitor (SSRI; Vakili, Gharraee, Habibi,
Lavasani, & Rasoolian, 2014). Thirty-two adults were assigned to ACT,
SSRI, or ACT + SSRI conditions. The ACT alone condition performed
similarly to the combined condition and both demonstrated large ef-
fects over the SSRI condition (ds = 1.14 and 1.28, respectively). Mean
Y-BOCS scores at pretreatment and posttreatment were as follows: ACT
23 and 14, SSRI 25 and 19, and ACT + SSRI 24 and 13. Finally, sixty
adults were randomized to group ACT, group time perspective therapy,
group narrative therapy, or wait-list conditions (Esfahani,
Kjbaf, & Abedi, 2015). ACT was the most eﬀective condition with mean
Y-BOCS scores at pretreatment, posttreatment, and follow-up as fol-
lows: ACT 28, 13, and 15; time perspective therapy 31, 28, 31; narrative
therapy 23, 18, 18, and waitlist 27, 27, 27. These results show large
eﬀects for ACT over the time perspective therapy at posttreatment (d=
4.88) and follow-up (d = 5.50), narrative therapy at posttreatment (d
= 1.64) and follow-up (d = .93), and wait-list at posttreatment (d =
3.84) and follow-up (d = 3.17). In summary, researchers out of Iran
have demonstrated consistent and positive ﬁndings for ACT across a
variety of conditions and have shown that ACT for OCD can be adapted
cross-culturally.
To continue to investigate the utility of ACT for OCD, the following
study will examine the eﬀects of group ACT on a sample of adults who
are already on a stable and optimal dose of SSRIs. The study will
compare group ACT + continued SSRIs vs continued SSRIs. This study
adds to the current literature on ACT and concurrent SSRI while re-
plicating aspects of a previous study (Vakili, Gharaee, & Habibi, 2015),
while adding follow-up data. It also includes data on rumination, which
is a central component in major depressive disorder, which occurs in
41% of those with OCD (American Psychiatric Association, 2013), and
is the largest predictor of poor treatment response in OCD (Knopp,
Knowles, Bee, Lovell, & Bower, 2013). Data on psychological ﬂexibility
was also collected, oﬀering information on processes of change in
therapy.
2. Method
2.1. Participants
The sample was recruited from six diﬀerent mental health centers in
Kashan, Iran. All participants were at optimal target doses of
Fluoxetine, Fluvoxamine, Citalopram, or Sertraline. Optimal does was
achieved by starting patients at low doses (Fluoxetine 20 mg,
Fluvoxamine 50 mg, Citalopram 10 mg, and Sertraline 50 mg) and in-
creasing every 3 or 4 days until maximum results with least side-eﬀects.
Inclusion criteria consisted of: (a) having a primary diagnosis of OCD
(identiﬁed from the Structured Clinical Interview for DSM-IV, Axis I
Disorders [SCID; First, Spitzer, Gibbon, &Williams, 1995]); (b) being
over 17 years old; (c) having at least a high school education; (d) being
female. Of note, Islamic customs make mixed-sex group therapy parti-
cipation diﬃcult, therefore a single sex group was run, as is common in
this culture. Exclusion criteria included: (a) a BDI-II score over 29; (b)
current diagnosis of bipolar disorder; (c) current psychotic episode; (d)
current suicide ideation; (e) a change in SSRI dose in the last 4 weeks;
(f) participation of psychological treatment in the last month; and (h)
planned changes in SSRI during the 16-week trial. A psychiatrist
screened 111 individuals for the study. Of those, 67 were then assessed
by a clinical psychologist who excluded 21 individuals based on in-
clusion and exclusion criteria. This resulted in 46 participants who were
randomly assigned, using a random number chart, to one of two
treatment conditions. Participant mean age was 27.91 (7.26), mean
duration of OCD symptoms was 20.28 (14.18) months, 45.7% had a
college degree, 82.6% were unemployed and not a current student, and
47.8% were married. See Table 1 for more detailed demographic in-
formation by condition. All participants in the ACT condition com-
pleted treatment. Two participants in the ACT condition did not com-
plete posttreatment assessments and an additional 5 did not complete
follow-up. Four participants in wait-list did not complete posttreatment
and an additional 3 did not complete follow-up assessments. This re-
sulted in 32 participants with complete data for the 16-week trial. See
Fig. 1 for a ﬂowchart of participants in the study.
2.2. Procedure
All participants were provided information about the two study
conditions and provided informed consent to participate in the study.
Eligible patients were randomly assigned to either continued SSRI
management or SSRI + group ACT. All participants provided demo-
graphic information at pretreatment. In addition, an assessment battery
was completed by participants at pretreatment, posttreatment, and a
two-month follow-up that included the measures listed in the measures
section. The SCID was only collected at pretreatment. The SCID has
demonstrated appropriate psychometric characteristics in the Iranian
community (Shariﬁ et al., 2009).
2.2.1. Continued SSRI management
The SSRI management condition consisted of the continued use of
SSRIs at the same levels prior to entering the study. Clients continued to
be monitored by the mental health center's psychiatrist. The dose of
SSRIs did not change during the 16-week trial. No psychological
treatment was provided during the trial period. Following the com-
pletion of the study, all participants in the SSRI management condition
participated in the same treatment provided to those in the ACT con-
dition.
2.2.2. Adjunctive Acceptance and Commitment Group Therapy (ACT)
The ACT condition consisted of SSRI management in addition to
eight sessions of group therapy split into three small groups using an
ACT treatment manual that closely followed the one used by Twohig
Table 1
Demographics by Treatment Condition.
ACT + SSRI
(n = 23)
SSRI
(n = 23)
t or χ2 p
Age M (SD) 29.13 (7.48) 26.70 (6.98) 1.14 .26
Duration of OCD (months) 22.26 (14.27) 18.30
(14.12)
.95 .35
Percent with College Degree 43.48% 57.83% .57 .90
Percent Married 52.20% 43.50% .35 .56
Percent Student or with
Occupation
26.10% 8.70% 2.42 .12
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et al. (2010). Groups were run by an ACT-trained therapist with three
years of ACT and group therapy experience. All sessions were audio-
taped and were reviewed weekly by a supervisor to establish internal
validity. All sessions had essential objectives that included: homework
and discussion of events between session, centering exercises, meta-
phors and in-session exercises adapted to Iranian culture, and group
discussion. Each session had a main objective based on ACT theory. In
order, these included: creative hopelessness, control as the problem and
introduction to acceptance, acceptance, defusion, self as context, con-
tact with present moment, values, and committed action.
2.3. Measures
2.3.1. Yale-Brown Obsessive Compulsive Scale, Self-Report
(Y-BOCS-SR; Steketee, Frost, & Bogart, 1996). The Y-BOCS-SR is a
ten-item, self-report questionnaire designed to assess OCD severity. The
sum of all items yields a total score (range = 0–40), with scores of 16 or
greater generally denoting clinically signiﬁcant levels of OCD symp-
toms. The scale has demonstrated good psychometric properties
(Steketee et al., 1996). The Y-BOCS-SR demonstrated acceptable relia-
bility in the current study (Cronbach's α = .73).
2.3.2. Beck Depression Inventory-II
(BDI-II; Beck, Steer, & Brown, 1996). The BDI-II is a commonly used,
self-report measure of depression. The measure consists of 21 items that
are summed to produce a total score (range = 0–63). Total scores are
classiﬁed into the following categories: minimal (0−13), mild
(14−19), moderate (20−28), and severe (29−63) (Beck et al., 1996).
The BDI-II has demonstrated good psychometric properties in Iranian
samples. The alpha coeﬃcient of the Iranian version is .86
(RAJABI & KARJO, 2013). The BDI-II demonstrated acceptable relia-
bility in the current study (Cronbach's α = .70).
2.3.3. Acceptance and Action Questionnaire
(AAQ-II; Bond et al., 2011). The AAQ-II is a 10-item, self-report
measure of psychological ﬂexibility. Items are summed to produce a
total score (range = 10–70), with higher scores representing greater
psychological ﬂexibility. The AAQ-II has demonstrated good psycho-
metric properties in Iranian samples. The alpha coeﬃcient of the Ir-
anian version is ranges from .71 to .89. (Abasi, Fti, Molodi, & Zarabi,
2013). The AAQ-II demonstrated good reliability in the current study
(Cronbach's α = .81).
2.3.4. Ruminative Response Scale
(RRS; Nolen-Hoeksema &Morrow, 1991). The RRS is a 22 item, self-
report measure of ruminative coping responses to depressed mood and
other negative symptoms. Items are summed to produce a total score
(range = 22–88) with higher scores denoting higher levels of rumi-
native coping style. The RRS has demonstrated good psychometric
properties (Wu, Zhang, Liu, Zhou, &Wei, 2015). The RSS demonstrated
good reliability in the current study (Cronbach's α = .85).
2.4. Data analysis
Kolmogrov-Smirnov and Levene's methods were used to test for
distribution normality and equality of variances (p< .05) and para-
metric tests were utilized for statistical analysis. Demographic data
were analyzed employing chi-square and independent two-sample
student's t-tests. Mixed models repeated measures (MMRM) analyses
were utilized to examine Time by Condition and main Time and
Condition eﬀects between the ACT/SSRI and SSRI treatment conditions
on outcome measures at pretreatment, posttreatment, and follow-up.
This method allows for analysis of the full intent-to-treat sample and all
available data points as any missing data points are modeled and in-
cluded in the analysis. Missing data were modeled in this fashion for 14
participants (30.43% of the sample). All participants completed pre-
treatment assessment, 14 did not complete follow-up, and of those, six
also did not complete posttreatment. Additional MMRM analyses were
utilized to examine within- and between-group changes for each out-
come measure. Analyses were also computed using repeated measures
ANOVA and results were the same with the exception that the between
conditions results for the Y-BOCS were signiﬁcant. We are choosing to
only report the intent to treat analyses using MMRM as it is the most
representative way to present between group time series analyses when
there is missing data.
3. Results
Independent sample t-test and Chi-square analysis showed no sig-
niﬁcant pretreatment diﬀerences (ps> .05) between the treatment
conditions for any demographic feature, indicating homogeneity be-
tween groups. See Table 1 for detailed demographic comparison results.
Fig. 1. Participant Flowchart.
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Table 2 displays descriptive statistics for each variable by treatment
condition at pretreatment, posttreatment, and follow-up, and Fig. 2
displays plots for the same data.
3.1. OCD symptom severity
MMRM analysis indicated a signiﬁcant Time × Condition interac-
tion for Y-BOCS-SR scores, F(2, 33.057) = 33.35, p< .001, Cohen's d =
2.01. Between-group comparisons indicated no signiﬁcant diﬀerence
between the treatment conditions at posttreatment t(38.778) =
−1.347, p = .186, d = 1.08, however, signiﬁcant diﬀerences were
found at follow up t(35.765) = −6.583, p< .001, d = 1.53. Within-
group comparisons indicated a signiﬁcant diﬀerence for the ACT/SSRI
condition from pre- to posttreatment t(20.011) =−10.052, p< .001, d
= 2.19 and from posttreatment to follow up t(15.840) = −7.511,
p< .001, d= 1.67. Signiﬁcant diﬀerences were also found for the SSRI
condition from pre- to posttreatment t(18.134) = −8.315, p< .001, d
= 1.90 and from posttreatment to follow up t(17.132) = −4.611,
p< .001, d = 1.10. These ﬁndings indicate that both treatment con-
ditions had a large, signiﬁcant impact on reducing OCD symptoms over
the treatment period that continued through follow-up; however, the
ACT + SSRI condition saw signiﬁcantly larger improvements at follow-
up than the SSRI condition. Moreover, from baseline to follow-up there
was, on average, a 71.3% improvement in Y-BOCS-SR scores in the ACT
+ SSRI condition compared to a 31.2% improvement in the SSRI
condition.
3.2. Depression symptom severity
BDI-II scores demonstrated a nonsigniﬁcant Time × Condition in-
teraction, F(2, 36.810) = 36.810, p = .089, Cohen's d = .53. However,
there was a signiﬁcant main eﬀect of Time, F(2, 36.810)=99.022,
p< .001, d = 3.28, but no main eﬀect of Condition, F(1, 40.654) =
2.820, p< .001, d = .53. Between group comparisons indicated no
signiﬁcant diﬀerence between the treatment conditions at posttreat-
ment t(38.778) = −1.347, p = .186, d = .42, however, a signiﬁcant
diﬀerence was found at follow up t(37.593) =−2.411, p = .021, d =
.79. Within-group comparisons indicated a signiﬁcant diﬀerence for the
ACT + SSRI condition from pre- to posttreatment t(20.374) =−8.463,
p< .001, d = 1.83 and from posttreatment to follow up t(15.874) =
−3.852, p = .001, d = .95. Signiﬁcant diﬀerences were also found for
the SSRI condition from pre- to posttreatment t(19.247) = −6.454,
p< .001, d = 1.42 and from posttreatment to follow up t(17.659) =
Table 2
Means and Standard Deviations at Pretreatment, Posttreatment, and Follow-Up by
Condition.
Measure ACT + SSRI (n = 16) SSRI (n = 16)
Pre Post Follow-up Pre Post Follow-up
YBOCS 22.62
(3.07)
13.50
(5.53)
6.50
(4.31)
21.25
(4.18)
17.56
(4.33)
14.62
(4.08)
BDI-II 19.31
(4.62)
9.13
(5.88)
5.12
(5.90)
17.75
(5.03)
10.25
(4.81)
7.68
(4.58)
RRS 54.06
(10.11)
34.63
(8.88)
27.31
(7.26)
50.75
(9.49)
39.43
(9.74)
33.87
(9.50)
AAQ-II 21.56
(6.13)
37.06
(6.58)
42.93
(5.05)
24.12
(4.75)
25.62
(5.40)
29.12
(3.86)
Note. MMRM analyses modeled data for participants who did not complete post and
follow-up assessments. This table reports only non-missing data. YBOCS = Yale Brown
Obsessive Compulsive Scale, Self Report; BDI-II = Beck Depression Inventory–II; RRS =
Ruminative Response Scale; AAQ-II = Acceptance and Action Questionnaire–II.
Fig. 2. Outcome Measures at Pretreatment, Posttreatment, and Follow-Up by Condition.
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−2.524, p= .021, d= .61. These ﬁndings indicate that both treatment
conditions had a similar, large impact on reducing depression symp-
toms over the treatment period that continued through follow-up;
however, there was a small, yet signiﬁcant diﬀerence between the
groups at follow-up indicating that the ACT + SSRI condition saw
greater symptom improvement than the SSRI condition.
3.3. Ruminative thoughts
RRS scores demonstrated a signiﬁcant Time × Condition interac-
tion, F(2, 40.282) = 6.706, p = .003, Cohen's d = .82. Between group
comparisons indicated signiﬁcant diﬀerences between the treatment
conditions at posttreatment t(42.046) = −2.823, p = .007, d = .88
and follow up t(37.880) =−3.217, p = .003, d = 1.06. Within-group
comparisons indicated a signiﬁcant diﬀerence for the ACT + SSRI
condition from pre- to posttreatment t(21.345) =−11.051, p< .001, d
= 2.37 and from posttreatment to follow up t(17.414) = −4.502,
p< .001, d= 1.07. Signiﬁcant diﬀerences were also found for the SSRI
condition from pre- to post-treatment t(19.659) =−5.865, p< .001, d
= 1.32 and from posttreatment to follow up t(17.596) = −4.292,
p< .001, d = 1.03. These ﬁndings indicate that both treatment con-
ditions had a large, signiﬁcant impact on reducing ruminative coping
responses over the treatment period that continued through follow-up;
however, the ACT + SSRI condition saw signiﬁcantly larger improve-
ments than the SSRI condition at post-treatment that were maintained
at follow-up.
3.4. Psychological ﬂexibility
AAQ-II scores demonstrated a signiﬁcant Time × Condition inter-
action, F(2, 38.706) = 40.395, p< .001, Cohen's d = 2.04. Between
group comparisons indicated signiﬁcant diﬀerences between the treat-
ment conditions at posttreatment t(38.752) = 6.849, p< .001, d =
2.16 and follow up t(33.741) = 9.565, p< .001, d = 3.24. Within-
group comparisons indicated a signiﬁcant diﬀerence for the ACT +
SSRI condition from pre- to post-treatment t(21.563) = −9.890,
p< .001, d = 2.13 and from posttreatment to follow up t(17.886) =
−3.859, p = .001, d = .91. Signiﬁcant diﬀerences were not found for
the SSRI condition from pre- to post-treatment t(18.704) = .896, p =
.382, d = .20, but were found from posttreatment to follow up t
(16.610) = 4.102, p = .001, d = .97. These ﬁndings indicate that
while both treatment conditions had signiﬁcant impact on increasing
psychological ﬂexibility from pre-treatment to follow-up, the ACT +
SSRI condition saw much larger and more immediate improvements
than the SSRI condition. Moreover, at follow-up there was, on average,
a 49.8% increase in AAQ-II scores in the ACT + SSRI condition com-
pared to a 17.2% increase in the SSRI condition.
4. Discussion
The present study demonstrated the impact of group ACT on a
sample who was at an optimal dose of SSRI versus continued SSRI
management. Speciﬁcally, both treatments lowered Y-BOCS-SR and
BDI-II scores from pre-to post-treatment, with ACT + SSRI lowering
them signiﬁcantly greater at follow-up. Secondary outcomes showed
that ACT + SSRI also reduced ruminative thought (as a mutual com-
ponent between obsessions and depression) more than SSRI.
Psychological ﬂexibility also changed more in the ACT + SSRI condi-
tion.
There are a number of important ﬁndings from this study. Most
notably, this study adds to the, now rather large, literature on ACT and
OCD. As covered in review papers (Bluett et al., 2014), there has been 1
randomized trial and many single subject designs testing the eﬀects of
ACT for OCD in the United States. Iranian researchers have continued
this work with two open trials (Izadi & Abedi, 2013; Izadi et al., 2012),
two randomized trials comparing ACT plus antidepressants to
antidepressants (Baghooli et al., 2014; Vakili et al., 2015), and one
randomized trial comparing ACT to two active control conditions and a
waitlist (Esfahani, Kjbaf, & Abedi, 2015). The current study adds to this
support while oﬀering some additional information. The results of all
the ACT for OCD studies are supportive of ACT over comparison con-
ditions, and achieving posttreatment and follow-up Y-BOCS-SR scores
that are in acceptable ranges. This mass of data across researchers lends
credibility to ACT as a method to address OCD.
This study replicates the ﬁndings that ACT + an antidepressant is
more eﬀective than the antidepressant alone (Baghooli et al., 2014;
Vakili et al., 2015), while even replicating the ﬁndings with SSRIs
(Vakili et al., 2015). It adds to the Vakili et al. (2015) study in that
follow-up was collected. The follow-up results showed ACT continued
to show gains well beyond SSRIs two months after treatment. This also
add to the Iranian work showing that group ACT for OCD is eﬀective.
This is important in that it highlights that these skills can be taught to a
larger group of individuals at one time. This is not surprising because
many studies testing ACT are completed with groups (A-Tjak et al.,
2015). It also adds to the literature on the eﬀects of ACT on depression
and ruminative thought.
Another notable ﬁnding is that the signiﬁcance between ACT+SSRI
and SSRI alone was not present until 2-month follow-up. Posttreatment
scores for ACT+SSRI were fairly typical for an OCD treatment trial. The
notable ﬁnding is that ACT + SSRI Y-BOCS scores were low at follow-
up. It is unclear what lead to this continued drop in scores after treat-
ment ended. While an increase between posttreatment and follow-up
has not been seen in ACT for OCD, neither has this continued decrease
from posttreatment to follow-up. Continued decreases like this have
been seen in other ACT trials, such as work with substance use and
abuse (Luoma, Kohlenberg, Hayes, & Fletcher, 2012). Unique features
of this study that could positively aﬀect follow-up and should be in-
vestigated include group treatment, female only sample, the sequencing
of SSRI and ACT, or the exclusion of those with high BDI scores. The
impact of these variables could be investigated in future studies.
There were several limitations in this study. First, the population of
interest was limited to females. While this would be uncommon in a
western society, the cultural rules and conventions in Iran make mixed-
sex therapy diﬃcult as participants are less likely to share content of
obsessions with members of the opposite sex. On the one hand, it limits
generalization, on the other hand, it demonstrates a cultural adaption of
a therapy to a particular group. Second, the sample size was small.
Combined with the Vakili study there is notable support for these
general ﬁndings. Third, follow-up duration for clinical outcomes was
only two months. Even though follow-up was not collected in the other
ACT + SSRI trial, a much longer duration would be preferable.
Repeated measurements of follow-up at 3, 6 and 12 months would be
useful. Fourth, the primary outcome was measured only by self-report.
While, the self-report version of the Y-BOCS has very good psycho-
metric properties and high correlations with clinician ratings of OCD
severity, a more objective measure is preferable to the self-report
method used in this study and should be employed in future trials. Fifth,
assessments and random assignment occurred after all participants
were already on SSRIs. Thus, this study really shows the additive eﬀects
of psychotherapy to medication versus continued medication. This is
still important because adding psychotherapy to medication is common
in the treatment of OCD, and it is useful to know it improves outcomes
over continued medication. Still, knowing the combined eﬀects versus
the stand-alone eﬀects of medication answers additional questions, such
as medication alone and the combination. Even though pretreatment Y-
BOCS scores are consisted with pretreatment scores in other published
outcome studies, pretreatment scores in the range of 22 is mild in terms
of OCD severity as the Y-BOCS has a maximum score of 40. Sixth,
participants only needed to be on stable dosages of SSRIs for 4 weeks
prior to enrolling in the study. Thus, they could still be experiencing
gains from the new medication during the study. Because participants
were randomly assigned, the eﬀects should have been balanced across
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conditions. Finally, the obsessive-compulsive complaints of participants
were mainly contamination-washing symptoms. This is partially a
product of the female only participants. Sexual and religious obsessions
are more prevalent in males, and females are more involved in con-
tamination/cleaning obsessions (Mathis et al., 2011). Even with these
limitations, this study notably adds to the literature on the treatment of
OCD in many ways.
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